CN100441199C - Spleen extracts, its preparation method and use - Google Patents
Spleen extracts, its preparation method and use Download PDFInfo
- Publication number
- CN100441199C CN100441199C CNB2005101027731A CN200510102773A CN100441199C CN 100441199 C CN100441199 C CN 100441199C CN B2005101027731 A CNB2005101027731 A CN B2005101027731A CN 200510102773 A CN200510102773 A CN 200510102773A CN 100441199 C CN100441199 C CN 100441199C
- Authority
- CN
- China
- Prior art keywords
- spleen
- clear liquid
- centrifugal
- spleen extract
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000952 spleen Anatomy 0.000 title claims abstract description 125
- 239000000284 extract Substances 0.000 title claims abstract description 97
- 238000002360 preparation method Methods 0.000 title claims abstract description 50
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 52
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 52
- 229920001184 polypeptide Polymers 0.000 claims abstract description 51
- 150000001413 amino acids Chemical class 0.000 claims abstract description 44
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 39
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 39
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 39
- 238000000108 ultra-filtration Methods 0.000 claims abstract description 31
- 238000010257 thawing Methods 0.000 claims abstract description 28
- 239000003814 drug Substances 0.000 claims abstract description 15
- 241000124008 Mammalia Species 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 14
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 8
- 208000000419 Chronic Hepatitis B Diseases 0.000 claims abstract description 6
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 6
- 201000002364 leukopenia Diseases 0.000 claims abstract description 6
- 231100001022 leukopenia Toxicity 0.000 claims abstract description 6
- 201000011510 cancer Diseases 0.000 claims abstract description 5
- 230000007969 cellular immunity Effects 0.000 claims abstract description 5
- 230000007812 deficiency Effects 0.000 claims abstract description 5
- 208000015181 infectious disease Diseases 0.000 claims abstract description 5
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 4
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 4
- 208000005647 Mumps Diseases 0.000 claims abstract description 4
- 208000007502 anemia Diseases 0.000 claims abstract description 4
- 208000002399 aphthous stomatitis Diseases 0.000 claims abstract description 4
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 4
- 208000032839 leukemia Diseases 0.000 claims abstract description 4
- 208000010805 mumps infectious disease Diseases 0.000 claims abstract description 4
- 201000009240 nasopharyngitis Diseases 0.000 claims abstract description 4
- 230000002980 postoperative effect Effects 0.000 claims abstract description 4
- 230000002685 pulmonary effect Effects 0.000 claims abstract description 4
- 230000000306 recurrent effect Effects 0.000 claims abstract description 4
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 4
- 206010043554 thrombocytopenia Diseases 0.000 claims abstract description 4
- 230000009385 viral infection Effects 0.000 claims abstract description 4
- 238000001556 precipitation Methods 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 101
- 238000002347 injection Methods 0.000 claims description 42
- 239000007924 injection Substances 0.000 claims description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 42
- 238000001914 filtration Methods 0.000 claims description 39
- 238000007710 freezing Methods 0.000 claims description 32
- 230000008014 freezing Effects 0.000 claims description 32
- 239000006228 supernatant Substances 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 26
- 238000005119 centrifugation Methods 0.000 claims description 21
- 239000012528 membrane Substances 0.000 claims description 21
- 238000010438 heat treatment Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 230000001105 regulatory effect Effects 0.000 claims description 15
- 239000008215 water for injection Substances 0.000 claims description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 11
- 239000012535 impurity Substances 0.000 claims description 11
- 239000000155 melt Substances 0.000 claims description 10
- 210000000577 adipose tissue Anatomy 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 7
- 208000024891 symptom Diseases 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 5
- 241000283690 Bos taurus Species 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- 241000282472 Canis lupus familiaris Species 0.000 claims description 3
- 241000282994 Cervidae Species 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 230000002650 habitual effect Effects 0.000 claims description 3
- 238000012805 post-processing Methods 0.000 claims description 3
- 210000002345 respiratory system Anatomy 0.000 claims description 3
- 238000013467 fragmentation Methods 0.000 claims description 2
- 238000006062 fragmentation reaction Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 abstract description 9
- 206010057190 Respiratory tract infections Diseases 0.000 abstract description 6
- 238000002512 chemotherapy Methods 0.000 abstract description 4
- 230000036541 health Effects 0.000 abstract description 4
- 238000001959 radiotherapy Methods 0.000 abstract description 3
- 208000035415 Reinfection Diseases 0.000 abstract 1
- 238000005238 degreasing Methods 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 48
- 235000001014 amino acid Nutrition 0.000 description 40
- 229940024606 amino acid Drugs 0.000 description 40
- 229940090044 injection Drugs 0.000 description 37
- 239000000047 product Substances 0.000 description 35
- 238000012360 testing method Methods 0.000 description 20
- 238000002156 mixing Methods 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 230000036039 immunity Effects 0.000 description 10
- 239000013558 reference substance Substances 0.000 description 10
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 210000003195 fascia Anatomy 0.000 description 7
- 230000036737 immune function Effects 0.000 description 7
- 210000004698 lymphocyte Anatomy 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 241000282898 Sus scrofa Species 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 4
- 244000309466 calf Species 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- 244000061458 Solanum melongena Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 229910000365 copper sulfate Inorganic materials 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012207 quantitative assay Methods 0.000 description 3
- 206010037833 rales Diseases 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000007779 soft material Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101710142246 External core antigen Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 235000014304 histidine Nutrition 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 210000002826 placenta Anatomy 0.000 description 2
- VZOPRCCTKLAGPN-ZFJVMAEJSA-L potassium;sodium;(2r,3r)-2,3-dihydroxybutanedioate;tetrahydrate Chemical compound O.O.O.O.[Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O VZOPRCCTKLAGPN-ZFJVMAEJSA-L 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000004400 serine Nutrition 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 229940074446 sodium potassium tartrate tetrahydrate Drugs 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000011003 system suitability test Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000288140 Gruiformes Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 208000019229 Spleen disease Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 102000007501 Thymosin Human genes 0.000 description 1
- 108010046075 Thymosin Proteins 0.000 description 1
- 108010074506 Transfer Factor Proteins 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000005262 decarbonization Methods 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005360 mashing Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001921 nucleic acid quantification Methods 0.000 description 1
- -1 pack Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- AVTYONGGKAJVTE-OLXYHTOASA-L potassium L-tartrate Chemical compound [K+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O AVTYONGGKAJVTE-OLXYHTOASA-L 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 208000027140 splenic disease Diseases 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- LCJVIYPJPCBWKS-NXPQJCNCSA-N thymosin Chemical compound SC[C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CO)C(=O)N[C@H](CO)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@H]([C@H](C)O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](C(C)C)C(=O)N[C@H](C(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@H](CCC(O)=O)C(O)=O LCJVIYPJPCBWKS-NXPQJCNCSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101027731A CN100441199C (en) | 2005-02-02 | 2005-09-15 | Spleen extracts, its preparation method and use |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200510005307.1 | 2005-02-02 | ||
CN200510005307 | 2005-02-02 | ||
CNB2005101027731A CN100441199C (en) | 2005-02-02 | 2005-09-15 | Spleen extracts, its preparation method and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1765371A CN1765371A (en) | 2006-05-03 |
CN100441199C true CN100441199C (en) | 2008-12-10 |
Family
ID=36741620
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101027731A Active CN100441199C (en) | 2005-02-02 | 2005-09-15 | Spleen extracts, its preparation method and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100441199C (en) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102450653A (en) * | 2010-10-22 | 2012-05-16 | 曹吉祥 | Animal spleen dry powder |
CN102475718A (en) * | 2010-11-23 | 2012-05-30 | 赵满达 | Transfer factor soluble powder for poultry, as well as preparation process and quality inspection method thereof |
CN103405751B (en) * | 2013-08-22 | 2015-05-20 | 赵轩 | Composition with cell repairing function and preparation method and application thereof |
CN103989709A (en) * | 2014-03-21 | 2014-08-20 | 江西赣南海欣药业股份有限公司 | Method for preparing oral solution containing pig spleen polypeptide and ribose |
CN103988971B (en) * | 2014-04-30 | 2015-12-02 | 南京农业大学 | A kind of extracting method of edible fowl liver protein |
CN104095879B (en) * | 2014-06-30 | 2018-01-23 | 卫材(辽宁)制药有限公司 | A kind of transfer factor solution and preparation method thereof |
CN104306401B (en) * | 2014-11-05 | 2018-01-12 | 吉林大学 | A kind of preparation of the sika deer deer spleen extract of function of increasing leukocyte and purposes |
CN104306400B (en) * | 2014-11-05 | 2018-01-12 | 吉林大学 | Application of the sika deer deer spleen extract in anti-oxidation medicine |
CN107344956A (en) * | 2017-08-18 | 2017-11-14 | 开封康诺药业有限公司 | A kind of extracting method of animal spleen extract |
CN109662263A (en) * | 2017-10-17 | 2019-04-23 | 江苏美中医疗科技有限公司 | A kind of dedicated diet of cancer dyscrasia patient |
CN107960653A (en) * | 2017-12-11 | 2018-04-27 | 长春三真实业有限公司 | A kind of spleen extract frozen dried food that can improve the elderly's body's immunity |
CN108095073A (en) * | 2017-12-11 | 2018-06-01 | 长春三真实业有限公司 | A kind of kidney extract frozen dried food that can improve old human organism's renal function |
CN111375048A (en) * | 2018-12-27 | 2020-07-07 | 北京第一生物化学药业有限公司 | Application of spleen aminopeptide in preparation of medicines for treating leukopenia |
CN114306269A (en) * | 2021-12-27 | 2022-04-12 | 西华大学 | Preparation method of lemon polypeptide effervescent tablets |
CN115624187B (en) * | 2022-12-08 | 2023-04-04 | 北京第一生物科技开发有限公司 | Application of bovine spleen peptide powder in improving sleep |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1089852A (en) * | 1993-01-21 | 1994-07-27 | 陈玉春 | The natural biological oral liquid that contains the bioactie agent nucleotide polypeptide type |
-
2005
- 2005-09-15 CN CNB2005101027731A patent/CN100441199C/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1089852A (en) * | 1993-01-21 | 1994-07-27 | 陈玉春 | The natural biological oral liquid that contains the bioactie agent nucleotide polypeptide type |
Also Published As
Publication number | Publication date |
---|---|
CN1765371A (en) | 2006-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100441199C (en) | Spleen extracts, its preparation method and use | |
CN1290862C (en) | Spleen polypeptide extract, its preparing process and use | |
CN102600219A (en) | Total flavone extract of abelmoschus manihot and preparing method of total flavone extract | |
CN1899361A (en) | Zhenqi medicinal composition and its preparation | |
EP2604272A1 (en) | Effective fraction from the fruiting bodies of ganoderma lucidum, extraction method, use and preparation thereof | |
EP2601219A2 (en) | Combination pharmaceutical composition and methods of treating and preventing the infectious diseases | |
CN103251926B (en) | Traditional Chinese medicine leech extract product and its application | |
CN111574586A (en) | Active peptide derived from Chinese JI Eupolyphaga Seu Steleophaga and having blood lipid reducing function, and preparation method and application thereof | |
CN103705754A (en) | Traditional Chinese medicine composition for treating systemic lupus erythematosus | |
CN100574768C (en) | A kind of anticancer pharmaceutical composition and its production and use | |
CN101687934B (en) | Pegylated erythropoietin conjugate and preparation method and uses thereof | |
CN101716319B (en) | Chinese medicine composition for treating hepatic fibrosis, and preparation method and applications thereof | |
CN101167755B (en) | Method for preparing centipede polysaccharide protein composition with anti-tumor activity and use | |
CN101032532B (en) | Medicine composition including active substrates extracted from Sang Huang, the preparing method and the application in the producing of medicine thereof | |
CN103845722A (en) | Oligopeptide composition for control of radiation damage or chemotherapy damage and preparation method thereof | |
CN114177244B (en) | Traditional Chinese medicine composition for treating thyroid cancer and preparation method thereof | |
CN101396373B (en) | Cinobufacini extract and preparation method thereof | |
CN101077372A (en) | Chinese medicinal materials composition for preventing and treating iron-deficiency anemia and method of making the same | |
CN100400051C (en) | Medicinal composition, and its preparing method and use | |
CN1771992A (en) | Brain extract and its prepn and use | |
CN114230646B (en) | Antitumor grifola frondosa glycoprotein and preparation method and application thereof | |
CN1108818C (en) | Activated immune globulin | |
CN101744770B (en) | Ginseng polysaccharide injection and preparation method thereof | |
CN103845720A (en) | Composition for control of radiation damage or chemotherapy damage and preparation method thereof | |
CN101402681A (en) | Polypeptide from deer floral disc, preparing method and uses for preventing and treating diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HU'NAN QIU ZEYOU PATENT STRATEGIC PLANNING CO., LT Free format text: FORMER OWNER: QIU ZEYOU Effective date: 20101028 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 410011 28/F, SHUNTIANCHENG, NO.59, SECTION 2 OF FURONG MIDDLE ROAD, CHANGSHA CITY, HU'NAN PROVINCE TO: 410205 JUXING INDUSTRY BASE, NO.8, LUJING ROAD, CHANGSHA HIGH-TECH. DEVELOPMENT ZONE, YUELU DISTRICT, CHANGSHA CITY, HU'NAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20101105 Address after: 135000 north section of Meihekou, Jilin, Zhujianglu Road Patentee after: Wansheng Lianhe Pharmaceutical Co., Ltd. Address before: 135000 No. 66, Xiangjiang Road, Meihekou, Jilin Patentee before: Duprofit Pharmacy Company Limited |
|
ASS | Succession or assignment of patent right |
Owner name: TONGHUA WINSUNNY UNION PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: WINSUNNY UNION PHARMACEUTICAL CO., LTD. Effective date: 20110920 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20110920 Address after: 135000 Jianguo Road, Jilin, Meihekou, No. 4455 Patentee after: Tonghua Wansheng United Pharmaceutical Co., Ltd. Address before: 135000 north section of Meihekou, Jilin, Zhujianglu Road Patentee before: Wansheng Lianhe Pharmaceutical Co., Ltd. |
|
C56 | Change in the name or address of the patentee |
Owner name: JILIN FENGSHENG PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: TONGHUA WANSHENG UNI-PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 135000 Jianguo Road, Jilin, Meihekou, No. 4455 Patentee after: Jilin Feng Sheng Pharmaceutical Co., Ltd. Address before: 135000 Jianguo Road, Jilin, Meihekou, No. 4455 Patentee before: Tonghua Wansheng United Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190828 Address after: Room 107, Office Building No. 1, Hongmei Industrial Park, Meihekou City, Tonghua City, Jilin Province Patentee after: Hongmei Pharmaceutical (China) Co., Ltd. Address before: 135000 Jianguo Road, Jilin, Meihekou, No. 4455 Patentee before: Jilin Feng Sheng Pharmaceutical Co., Ltd. |
|
TR01 | Transfer of patent right |
Effective date of registration: 20201222 Address after: No.4455 Jianguo Road Meihekou Tonghua Jilin 135000 Patentee after: Rongzhi Fengsheng Pharmaceutical Co.,Ltd. Address before: 135000 room 107, office building 1, Hongmei Industrial Park, Meihekou, Tonghua, Jilin Province Patentee before: HOLWRAY PHARMACEUTICAL (CHINA) Co.,Ltd. |
|
TR01 | Transfer of patent right |